ANIKANIKHealthcare · Drug Manufacturers - Specialty & Generic

ANIK Stock Forecast: Anika Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$14
+5.99% on the day

The 2 Wall Street analysts covering Anika Therapeutics, Inc. hold a median 12-month price target of $20 — +46.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$172.1M
Ticker Nerd rank
98/ 100
Median analyst target
$20
Analysts covering
2
Revenue$32.6M+15.6% y/y
Operating income$3.0M
Net income$3.3M
Free cash flow−$2.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.4%
1M
−31.8%
YTD
+41.7%
1Y
+40.8%
From 52W high
−38.2%
From 52W low
+49.2%
$9
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANIK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anika Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
98/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Momentum
88
Quality
78
Growth
76
Issuance
75
Revisions
71
Size
67
Accruals
54
Volatility
49

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (49): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ANIK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Jan 26Apr 26Jul 26Oct 26ANIKHigh $23Median $20Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $17Median $20High $23

The green dot is the last close — the median target sits +46.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
16 Nov 2026B. Riley SecuritiesReiteratesBuy$23 → $17
18 Sept 2026B. Riley SecuritiesAssumesBuy$21 → $23
30 July 2026B. Riley SecuritiesMaintainsBuy—
30 July 2026B. Riley SecuritiesMaintainsBuy$18 → $21
27 Feb 2026Barrington ResearchMaintainsOutperform$16 → $17
27 Feb 2026Barrington ResearchMaintainsOutperform—
9 Jan 2026Barrington ResearchMaintainsOutperform—
6 Nov 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
31 July 2025Barrington ResearchMaintainsOutperform—
12 May 2025Barrington ResearchMaintainsOutperform—
13 Mar 2025Barrington ResearchMaintainsOutperform—
1 Nov 2024Barrington ResearchMaintainsOutperform—
22 Oct 2024Barrington ResearchMaintainsOutperform—
9 Aug 2024Barrington ResearchMaintainsOutperform—
29 May 2024Stephens & Co.ReiteratesEqual-Weight—
9 May 2024Barrington ResearchMaintainsOutperform—
14 Mar 2024Barrington ResearchMaintainsOutperform—
14 Mar 2024Stephens & Co.ReiteratesEqual-Weight—
3 Jan 2024Barrington ResearchMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ANIK appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ANIK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Anika Therapeutics, Inc. returned +40.8% against +12.2% for the S&P 500, dividends included.

ANIK vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26ANIKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANIK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Anika Therapeutics, Inc. (ANIK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.7×

Cheaper than 96% of US stocks

Price / sales
1.5×

Cheaper than 58% of US stocks

Price / book
1.3×

Cheaper than 59% of US stocks

EV / EBITDA
27.6×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
10.0%

Higher than 53% of US stocks

Earnings growth (YoY)
15.6%

Higher than 55% of US stocks

Gross margin
65.1%

Higher than 78% of US stocks

Operating margin
−0.1%

Higher than 33% of US stocks

Net margin
−1.4%

Higher than 27% of US stocks

Returns & dividend
Return on equity
−0.2%

Higher than 43% of US stocks

Return on assets
−0.0%

Higher than 43% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Anika Therapeutics, Inc. (ANIK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anika Therapeutics, Inc. has a market value of $172.1M and an enterprise value of $153.3M.

  • Revenue in the twelve months to 30 June 2026: $120.7M. The latest quarter grew 10.0% year on year.

  • Net income over the same four quarters: −$3.8M, a −3.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.27.

  • Free cash flow in the twelve months to 30 June 2026: $562K.

  • Anika Therapeutics, Inc. spent $15.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 13.3M.

  • Trailing P/E: −17.7×; forward P/E: 13.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Anika Therapeutics, Inc. employs 235 people — $513K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

ANIK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ANIKAnika Therapeutics, Inc.$172.1M98
ADCTADC Therapeutics SA$189.9M86
SIGASIGA Technologies, Inc.$195.6M51
BIOABioAge Labs, Inc.$226.3M16
LFCRLifecore Biomedical, Inc.$242.2M2
BGMBGM Group Ltd.$108.6M43
AKBAAkebia Therapeutics, Inc.$107.3M44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anika Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANIK news & analysis

Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript

Seeking Alpha · 6 Nov 2026neutral

Seeking Alpha published a transcript of Anika Therapeutics’ Q3 2026 earnings call. The excerpt provides no further details about the call.

Why it matters — ANIK watchers may consult the transcript for the company’s Q3 2026 earnings-call discussion, but no specific results or commentary are included in the excerpt.

What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call

MarketBeat · 6 Nov 2026neutral

Anika Therapeutics reported a 10% increase in third-quarter revenue and raised the lower end of its 2026 revenue and adjusted EBITDA margin forecasts. It lowered its commercial channel growth outlook following slower U.S. elective surgery activity.

Why it matters — ANIK watchers may focus on the combination of improved forecast floors and a softer commercial channel outlook tied to slower elective surgery activity.

Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates

Zacks Investment Research · 6 Nov 2026positive

Anika Therapeutics reported quarterly earnings of $0.29 per share, above the Zacks Consensus Estimate of $0.17. Earnings were $0.04 per share in the year-ago quarter.

Why it matters — ANIK watchers may note the reported earnings exceeded the consensus estimate and were higher than a year earlier.

Anika Reports Third Quarter 2026 Financial Results

GlobeNewsWire · 6 Nov 2026positive

Anika reported third-quarter 2026 revenue growth of 10% year over year, led by 17% growth in its commercial channel and more than 30% growth in Integrity revenue. The company also announced a new 10-year Hyvisc partnership, reintroduced a Hyaff non-orthopedic OEM product, and raised the lower end of its 2026 revenue guidance and its 2026 adjusted EBITDA guidance.

Why it matters — The results and raised guidance provide ANIK watchers with updates on quarterly growth, commercial initiatives, and the company’s 2026 outlook.

Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026

GlobeNewsWire · 22 Oct 2026neutral

Anika Therapeutics announced it will release its third-quarter 2026 financial results before market open on November 6, 2026. A conference call to discuss the results and business highlights is scheduled for 8:30 a.m. ET.

Why it matters — ANIK watchers can note the date and time when the company plans to report results and provide business updates.

FAQ

Frequently asked questions about ANIK stock

What is the ANIK stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Anika Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $17 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIK stock a buy right now?

Of the 2 analysts covering Anika Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anika Therapeutics, Inc. 98 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIK?

As at 17 Nov 2026, Anika Therapeutics, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will ANIK stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +46.8% from the last close, and Ticker Nerd's factor model ranks Anika Therapeutics, Inc. 98 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIK stock forecast for 2030?

No analyst covering Anika Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $23 over the next 12 months.

How has ANIK stock performed over the past year?

Anika Therapeutics, Inc. returned +40.8% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anika Therapeutics, Inc. do?

Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics.

What is the latest news on ANIK?

The most recent item we track (Seeking Alpha, 6 Nov 2026): "Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Anika Therapeutics’ Q3 2026 earnings call. The excerpt provides no further details about the call.

Company

About Anika Therapeutics, Inc.

Anika Therapeutics Inc. is a medical technology company focused on joint preservation and early intervention orthopedics. The company develops, manufactures, and commercializes hyaluronic acid-based products used in osteoarthritis pain management, regenerative medicine, sports medicine, and soft tissue repair. Its portfolio includes injectable therapies and orthopedic solutions designed to support mobility, tissue healing, and minimally invasive care for patients with degenerative joint conditions and musculoskeletal injuries. Anika Therapeutics serves healthcare professionals and clinical settings across the United States, Europe, and other international markets, with products used in orthopedics and related surgical applications. Headquartered in Bedford, Massachusetts, Anika Therapeutics Inc. plays a specialized role in the musculoskeletal care market by offering therapies and biomaterials that address joint health, cartilage repair, and recovery support.

CEO Mr. Stephen D. Griffin · 235 employees · United States · https://www.anika.com